Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review.
Journal
Immunotherapy
Journal Volume
16
Journal Issue
2
ISSN
1750-7448
Date Issued
2024-02
Author(s)
Hsieh, Tyng-Shiuan
Abstract
ackground: Oral conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), especially methotrexate, are the cornerstone of treating psoriatic arthritis (PsA). The use of csDMARDs with biologics has increased their efficacy in psoriasis. However, the combination of two oral DMARDs in patients with PsA has not been adequately reviewed. In this study, we explore the combinational use of methotrexate with DMARDs in PsA patients. Materials & methods: A review was conducted using Medline (PubMed), Embase, Web of Science and the Cochrane Library, covering articles up to February 2023. Results & conclusion: Nine studies comprising 1993 participants were included. The evidence supporting combination therapy remains limited. Combinational therapy could be considered in patients with inadequate response to monotherapy or no access to biologics.
Subjects
combination therapy
conventional synthetic disease-modifying antirheumatic drugs
evidence-based dermatology
methotrexate
pharmacology
targeted synthetic disease-modifying antirheumatic drugs
SDGs
Type
review